Apple at its earnings call earlier this month revealed that the iPhone SE had a big hand in the double digit growth in iPhone sales in India this last quarter. Now, a fresh report claims Apple is preparing to launch the iPhone SE’s successor in early 2018, corroborating a much earlier report. The new model, said to be called the iPhone SE 2, will reportedly be manufactured by Taiwanese original design manufacturer (ODM) Wistron at its Bengaluru factory that already produces the original iPhone SE.
As per a fresh supply-chain report by Taiwan’s Economic Daily News, Apple will launch the iPhone SE 2 in the first quarter of next year. The reported launch schedule appears to be in line with the original iPhone SE that was debuted in March last year. Further, the new low-end iPhone model is reportedly already in the initial stages of production at Wistron’s facility in Bengaluru. The facility was established for assembling iPhone SE models earlier this year, allowing Apple to enjoy reduced tariffs by adhering to the Make in India and thereby reduce prices on the smartphone.
The local manufacturing process is already helping Apple maintain an affordable price of the iPhone SE in India. This trend would continue with its refresh version. According to the FDI (Foreign Direct Investment) policy, foreign companies producing goods in the country need to source 30 percent of their components locally. Therefore, the iPhone SE 2 is likely to be marketed as a new “Made in India” iPhone by the Cupertino company.
The report adds that the iPhone SE 2 will be targeted at markets like Indonesia and the rest of Southeast Asia, apart from India. It is also said to cost roughly $450 (roughly Rs. 29,200) – which if true would be significantly cheaper than the original iPhone SE’s launch price.
If we believe some recent reports, the second-generation iPhone SE will have Apple’s A10 Fusion chip that was debuted on the iPhone 7 and iPhone 7 Plus last year, coupled with 2GB of RAM as well as 32GB and 128GB storage options. The iPhone SE 2 is also rumoured to have a 12-megapixel rear camera sensor, a 5-megapixel front camera, and a 1700mAh battery. Moreover, the display of the new iPhone SE model is likely to be identical to its predecessor that has a 4-inch panel.
Apple can be expected to announce the iPhone SE model in March, if going by last year’s launch. Meanwhile, we can expect a series of rumours and leaks pointing towards the new hardware.
Biocon share price gained 2.5 percent intraday Thursday after the biopharmaceuticals firm has launched KRABEVA, a biosimilar Bevacizumab, in India.
The drug is used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.
“We believe KRABEVA will be an important addition to oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India,” Arun Chandavarkar, CEO and joint MD, Biocon said.
KRABEVA is the second key oncologic biosimilar product from Biocon’s global biosimilars portfolio to be launched in India, in order to address the unmet patient need for affordable biological therapies.
The product is being offered to patients at an MRP of Rs 24,000 for 100 mg / 4 ml vials and Rs 39,990 for 400 mg / 16 ml vials.
KRABEVA is being launched post successful completion of phase III clinical trials and approval of company’s marketing authorisation application by the Drug Controller General of India.
At 11:02 hours IST, the stock price was quoting at Rs 418.50, up Rs 9.90, or 2.42 percent on the BSE.
Shares of Biocon jumped as much as 2.65 per cent in Tuesday as the company has launched its cancer biosimilar drug KRABEVA in India.
Following a positive open at Rs 410 against the previous close of Rs 408.60, the scrip touched an intraday high of Rs 419.75 and a low of Rs 405.80. In terms of equity volume, 10.29 lakh shares traded on the BSE.
The stock ended the session up by 1.09 per cent at Rs 413.05.
According to a BSE filing, the biosimilar product will be used for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India.
Biocon CEO and Joint MD Arun Chandavarkar said: “With KRABEVA, we intend to provide a high quality, world-class biosimilar Bevacizumab as an affordable therapy option for patients of various types of cancer.”
The company believes that the product will be an important addition to its oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India, he added.
The SpaceX Falcon 9 lifting off in Florida on 11 October this year. Photograph: SpaceX/flickr
SpaceX set a brisk pace this week, with two successful launches of the Falcon 9 rocket. The second launch by the company – whose chief executive is its billionaire founder, Elon Musk – re-used a previously flown first stage booster, increasing confidence that SpaceX could deliver re-useable rockets and so drive down launch costs.
The first launch took place on 9 October. The rocket lifted off from the Vandenberg airforce base in California at 05:37 PDT (12:37 GMT). It placed 10 communications satellites in a 400-mile-high orbit for Iridium, the telecommunications company.
Iridium runs a constellation of telecommunications satellites. This launch is the first of eight launches scheduled that will place 75 satellites in orbit for the company.
On 11 October a second Falcon 9 rocket lifted off, this time from Kennedy Space Centre, in Florida. The launch took place at 18:53 EDT (22:53 GMT), and carried a larger communications satellite into orbit for SES and EchoStar.
This second launch was notable because it re-used a previously flown Falcon 9 first stage. This part of the rocket first launched last February when it boosted a Dragon cargo ship to the International Space Station; it then flew back and soft landed in Florida for re-use. This booster has now landed back on Earth again, several hundred miles from Cape Canaveral on a drone ship.
Reusing significant spacecraft components is the key to SpaceX’s business model of reducing launch costs. After each flight this week all the first stages returned safely to Earth.
These launches bring the total of SpaceX launches this year to 15, establishing the company as a leading player in the satellite launch market. In September, Musk declared his intention to use his rockets to colonise Mars.